Table 3.
Average Uosm in response to tolvaptan or placebo (EOT) and corresponding baseline eGFR
| Average Uosm at EOT, mOsm/kg | Treatment (N) | Average Dose of Tolvaptan at EOT, mg/d | Baseline eGFR, ml/min per 1.73m2 |
|---|---|---|---|
| <200 | Tolvaptan (324) | 104 | 77.1±20.4 |
| Placebo (15) | — | 84.3±21.9 | |
| 200–<300 | Tolvaptan (215) | 97 | 80.2±20.5 |
| Placebo (43) | — | 76.2±18.9 | |
| 300–<400 | Tolvaptan (92) | 92 | 89.3±21.5 |
| Placebo (66) | — | 74.9±23.0 | |
| 400–<500 | Tolvaptan (31) | 92 | 93.1±19.6 |
| Placebo (101) | — | 79.3±22.1 | |
| ≥500 | Tolvaptan (4) | 67 | 102±24.1 |
| Placebo (107) | — | 91.6±22.7 |
eGFR values are mean±SD. —, not dosed.